Parameters | Infants with type 1 ROP (n=70, 131 eyes) | Infants with aggressive ROP (n=24, 45 eyes) | P value |
Gestational age, weeks | 25.7±1.8 | 25.2±2.0 | 0.2311 |
Birth weight, g | 832.01±274.84 | 824.21±311.87 | 0.9079 |
ROP zone at primary treatment, eyes | |||
Zone I | 18 eyes | 20 eyes | <0.0001* |
Posterior zone II | 34 eyes | 6 eyes | |
Zone II | 79 eyes | 19 eyes | |
PMA at primary treatment, weeks | 38.3±6.1 | 35.6±3.4 | 0.0003* |
Primary treatment choice, eyes | |||
Anti-VEGF injection monotherapy | 97 eyes | 40 eyes | 0.1075 |
Laser ablation monotherapy | 32 eyes | 5 eyes | |
Combination (anti-VEGF+laser treatment) | 2 eyes | none | |
Time of plus disease disappearance after primary treatment, days | 17.9±16.3 ~ not disappear | 28.7±14.1 ~ not disappear | 0.0467* |
Additional treatment-requiring eyes | 35 eyes (26.72%) | 25 eyes (55.56%) | 0.0004* |
Values of gestational age, birth weight, PMA at primary treatment and periods of plus disease disappearance in each group are presented as mean±SD.
*Statistically significant by the Pearson’s χ2 test or Fisher’s exact test.
anti-VEGF, antivascular endothelial growth factor.PMA, postmenstrual age; ROP, retinopathy of prematurity;